Roles of rictor in mTOR signaling, differentiation & immune memory via Akt & PKC

rictor 在 mTOR 信号传导、分化中的作用

基本信息

  • 批准号:
    8053503
  • 负责人:
  • 金额:
    $ 38.85万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-01-15 至 2014-11-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Analyses of signaling mechanisms drive fundamental insights into biological regulation as well as important targets for possible therapeutic interventions. Adaptive immunity and autoimmune disease are determined by signal transduction pathways that regulate the balance among differentiation and fate choices for CD4 and CD8 T cells, and the capacities of different subsets to generate immunological memory. Signals initiated through PI 3-kinases (PI3K) are relayed in part by the pro-survival kinase Akt, whose activation and downstream targets such as the mammalian Target of Rapamycin (mTOR) regulate survival and proliferation. Functions of rapamycin, an immune suppressive drug useful in transplantation medicine, had been equated with mTOR inhibition, but recent findings show that mTOR functions through at least two mutually exclusive classes of multiprotein complexes. The first, mTORC1, is rapamycin-sensitive and regulates aspects of protein translation and cellular growth. However, a second class of mTOR complex, termed mTORC2, is relatively rapamycin-resistant, with inhibition depending on the effective concentration of the drug. While the signaling and biology of mTORC1 have been investigated extensively, little is known about the roles of mTORC2 in normal cell physiology, and nothing in cells of the immune system. Evidence as to the function of mTORC2 in immunity (if any), the mechanism(s) for any such function or its relation to Akt vs. PKC pathways, and whether or not the lack of mTORC2 would mitigate abnormalities stemming from loss of PTEN in lymphocytes are all unknown. Exciting indications suggest complex roles of rapamycin in regulating a balance between effector and memory states for CTL, but nothing is known about the helper lineages in this regard, nor is there insight into how mTORC2 relates to the effect of rapamycin on CTL memory. Thus, the need to understand functions of the mTORC2 complex as part of new frontiers for mTOR signaling in immunity and memory is especially great. Based on our preliminary findings, the central hypotheses of this proposal are (i) that the mTORC2 signaling complex mediates the acquisition of full and appropriately balanced functional capabilities by mature T cells, and (ii) that it regulates their properties and capacity to participate in immunity and autoimmunity using different downstream signal relays depending on the biological target process. To test the central hypothesis and elucidate related mechanisms, we propose to define the roles of mTORC2 in T cell- mediated primary and recall immunity (Aim 1), elucidate mechanisms by which mTORC2 effects T helper differentiation via the HM modifications of Akt- and PKC-8 (Aim 2), and dissect the interplay between mTORC2 and PTEN in regulating T cells (Aim 3). The expected outcome of the proposed studies is that we will (i) change concepts and elucidate how mTOR signaling affects immunity and CD4 T cell fates, & (ii) identify new mechanisms by which signaling through Akt and PKC influence the balance of gene expression programs acquired by this class of T cells, thereby offering the potential for more selective therapeutic targeting. PUBLIC HEALTH RELEVANCE: The precise properties of a class of white blood cells called lymphocytes are central to the effectiveness of immune responses and vaccines but also cause autoimmune diseases and the rejection of organ transplants. Lymphocytes acquire their specific properties as a result of passing signals inside the cell, a feature exploited by effective but problematic immune suppressant drugs such as rapamycin. This research proposal seeks to understand key aspects of how proteins whose function is blocked by rapamycin function in immunity by regulating lymphocytes, and enhance understanding of the way in which vaccines work through 'immune memory'.
描述(由申请人提供):对信号机制的分析推动了对生物调节的基本见解,以及可能的治疗干预的重要目标。获得性免疫和自身免疫性疾病是由信号转导通路决定的,这些信号转导通路调节CD4和CD8T细胞分化和命运选择之间的平衡,以及不同亚群产生免疫记忆的能力。通过PI3K启动的信号部分由促生存的蛋白激酶Akt传递,Akt的激活和下游靶标如哺乳动物靶标雷帕霉素(MTOR)调节生存和增殖。雷帕霉素是一种用于移植医学的免疫抑制药物,其作用被等同于mTOR抑制,但最近的研究发现,mTOR至少通过两类相互排斥的多蛋白复合体发挥作用。第一个是mTORC1,对雷帕霉素敏感,调节蛋白质翻译和细胞生长的各个方面。然而,第二类mTOR复合体,称为mTORC2,对雷帕霉素相对耐药,抑制作用取决于药物的有效浓度。虽然mTORC2的信号和生物学已经被广泛研究,但对mTORC2在正常细胞生理中的作用知之甚少,在免疫系统的细胞中也是如此。关于mTORC2在免疫中的功能(如果有)的证据,任何这种功能的机制(S)或它与Akt和PKC通路的关系,以及mTORC2的缺乏是否可以减轻淋巴细胞中PTEN缺失引起的异常,都是未知的。令人兴奋的迹象表明,雷帕霉素在调节CTL效应器和记忆状态之间的平衡方面发挥了复杂的作用,但对这方面的辅助谱系尚不清楚,也没有深入了解mTORC2与雷帕霉素对CTL记忆的影响。因此,了解mTORC2复合体作为mTOR信号在免疫和记忆中的新前沿的功能的必要性特别大。根据我们的初步发现,这一建议的中心假设是(I)mTORC2信号复合体介导成熟T细胞获得充分和适当平衡的功能,以及(Ii)它根据生物靶过程的不同下游信号传递调节其参与免疫和自身免疫的性质和能力。为了验证中心假设并阐明相关机制,我们建议定义mTORC2在T细胞介导的初级免疫和回忆免疫中的作用(目标1),阐明mTORC2通过Akt-和PKC-8的HM修饰影响辅助性T细胞分化的机制(目标2),并剖析mTORC2和PTEN在调节T细胞中的相互作用(目标3)。拟议研究的预期结果是:我们将(I)改变概念并阐明mTOR信号如何影响免疫和CD4T细胞命运,以及(Ii)确定通过Akt和PKC信号影响这类T细胞获得的基因表达程序平衡的新机制,从而提供更具选择性的治疗靶向的可能性。 与公共卫生相关:一种名为淋巴细胞的白细胞的精确特性是免疫反应和疫苗有效性的核心,但也会导致自身免疫性疾病和器官移植排斥反应。淋巴细胞通过在细胞内传递信号而获得其特定的特性,这一特性被雷帕霉素等有效但有问题的免疫抑制药物所利用。这项研究计划试图了解那些功能被雷帕霉素阻断的蛋白质如何通过调节淋巴细胞在免疫中发挥作用的关键方面,并加强对疫苗通过“免疫记忆”发挥作用的方式的理解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Mark R Boothby其他文献

Mark R Boothby的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Mark R Boothby', 18)}}的其他基金

Antibody quality and germinal center requirements for peroxisomal function in lymphocytes
淋巴细胞过氧化物酶体功能的抗体质量和生发中心要求
  • 批准号:
    10469589
  • 财政年份:
    2021
  • 资助金额:
    $ 38.85万
  • 项目类别:
Antibody quality and germinal center requirements for peroxisomal function in lymphocytes
淋巴细胞过氧化物酶体功能的抗体质量和生发中心要求
  • 批准号:
    10318012
  • 财政年份:
    2021
  • 资助金额:
    $ 38.85万
  • 项目类别:
Effect of tumor cell glutamine metabolism on anti-tumor immunity in TNBC
TNBC肿瘤细胞谷氨酰胺代谢对抗肿瘤免疫的影响
  • 批准号:
    10430078
  • 财政年份:
    2020
  • 资助金额:
    $ 38.85万
  • 项目类别:
Effect of tumor cell glutamine metabolism on anti-tumor immunity in TNBC
TNBC肿瘤细胞谷氨酰胺代谢对抗肿瘤免疫的影响
  • 批准号:
    10219207
  • 财政年份:
    2020
  • 资助金额:
    $ 38.85万
  • 项目类别:
Effect of tumor cell glutamine metabolism on anti-tumor immunity in TNBC
TNBC肿瘤细胞谷氨酰胺代谢对抗肿瘤免疫的影响
  • 批准号:
    10656440
  • 财政年份:
    2020
  • 资助金额:
    $ 38.85万
  • 项目类别:
Manipulating & imaging nutrient micro-milieux as B cells effect humoral immunity
操纵
  • 批准号:
    10529278
  • 财政年份:
    2019
  • 资助金额:
    $ 38.85万
  • 项目类别:
Manipulating & imaging nutrient micro-milieux as B cells effect humoral immunity
操纵
  • 批准号:
    10062829
  • 财政年份:
    2019
  • 资助金额:
    $ 38.85万
  • 项目类别:
Manipulating & imaging nutrient micro-milieux as B cells effect humoral immunity
操纵
  • 批准号:
    9889587
  • 财政年份:
    2019
  • 资助金额:
    $ 38.85万
  • 项目类别:
Manipulating & imaging nutrient micro-milieux as B cells effect humoral immunity
操纵
  • 批准号:
    10306395
  • 财政年份:
    2019
  • 资助金额:
    $ 38.85万
  • 项目类别:
Fit to remember? B cell metabolic 'fitness', AMPK & recall antibody responses
适合记住吗?
  • 批准号:
    9204785
  • 财政年份:
    2015
  • 资助金额:
    $ 38.85万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.85万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.85万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 38.85万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.85万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.85万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.85万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.85万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 38.85万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 38.85万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
  • 批准号:
    2244994
  • 财政年份:
    2023
  • 资助金额:
    $ 38.85万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了